| ［1］ |
Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. treatment［J］. Eur J Cancer, 2020,128:83⁃102. doi: 10.1016/j.ejca.2020.01.008.
|
| ［2］ |
Soura E, Gagari E, Stratigos A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?［J］. Curr Opin Oncol, 2019,31（5）:461⁃468. doi: 10.1097/CCO.0000000000000566.
|
| ［3］ |
Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention［J］. Eur J Cancer, 2020,128:60⁃82. doi: 10.1016/j.ejca.2020.01.007.
|
| ［4］ |
Dereure O, Missan H, Girard C, et al. Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients［J］. Dermatology, 2016,232（6）:721⁃730. doi: 10.1159/000461578.
|
| ［5］ |
Maubec E, Petrow P, Scheer⁃Senyarich I, et al. Phase II study of cetuximab as first⁃line single⁃drug therapy in patients with unresectable squamous cell carcinoma of the skin［J］. J Clin Oncol, 2011,29（25）:3419⁃3426. doi: 10.1200/JCO.2010.34.1735.
|
| ［6］ |
Montaudié H, Viotti J, Combemale P, et al. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study［J］. Oncotarget, 2020,11（4）:378⁃385. doi: 10.18632/oncotarget.27434.
|
| ［7］ |
Foote MC, McGrath M, Guminski A, et al. Phase II study of single⁃agent panitumumab in patients with incurable cutaneous squamous cell carcinoma［J］. Ann Oncol, 2014,25（10）:2047⁃2052. doi: 10.1093/annonc/mdu368.
|
| ［8］ |
Hourbeigt K, Ehret M, Visseaux L, et al. Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:2789⁃2794. doi: 10.1111/ jdv.16465.
|
| ［9］ |
Marti A, Fauconneau A, Ouhabrache N, et al. Complete remission of squamous cell carcinoma after treatment with panitumumab in a patient with cetuximab⁃induced anaphylaxis［J］. JAMA Dermatol, 2016,152（3）:343⁃345. doi: 10.1001/jamadermatol. 2015.4134.
|
| ［10］ |
Glisson BS, Kim ES, Kies MS, et al. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin［J］. J Clin Oncol, 2006,24（18_suppl）:5531. doi: 10. 1200/jco.2006.24.18_suppl.5531.
|
| ［11］ |
William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single⁃arm phase II clinical trial［J］. J Am Acad Dermatol, 2017,77（6）:1110⁃1113.e2. doi: 10.1016/j.jaad.2017.07.048.
|
| ［12］ |
Gold KA, Kies MS, William WN Jr, et al. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single⁃arm phase 2 clinical trial［J］. Cancer, 2018,124（10）:2169⁃2173. doi: 10.1002/cncr.31346.
|
| ［13］ |
Read WL, Brumund KT, Weisman RA, et al. Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases［J］. JAAD Case Rep, 2015,1（3）:153⁃156. doi: 10.1016/j.jdcr.2015.02.014.
|
| ［14］ |
Cavalieri S, Perrone F, Miceli R, et al. Efficacy and safety of single⁃agent pan⁃human epidermal growth factor receptor （HER） inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer［J］. Eur J Cancer, 2018,97:7⁃15. doi: 10.1016/j.ejca.2018.04.004.
|
| ［15］ |
Jenni D, Karpova MB, Mühleisen B, et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis［J］. ESMO Open, 2016,1（1）:e000003. doi: 10.1136/esmoopen⁃2015⁃000003.
|
| ［16］ |
Strickley JD, Spalding AC, Haeberle MT, et al. Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib［J］. Exp Hematol Oncol, 2018,7:20. doi: 10.1186/s40164⁃018⁃0111⁃z.
|
| ［17］ |
Cañueto J, Cardeñoso E, García JL, et al. Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma［J］. Br J Dermatol, 2017,176（5）:1279⁃1287. doi: 10.1111/bjd.14936.
|
| ［18］ |
Boutros A, Cecchi F, Tanda ET, et al. Immunotherapy for the treatment of cutaneous squamous cell carcinoma［J］. Front Oncol, 2021,11:733917. doi: 10.3389/fonc.2021.733917.
|
| ［19］ |
Rischin D, Khushalani NI, Schmults CD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow⁃up of outcomes and quality of life analysis［J］. J Immunother Cancer, 2021,9（8）:e002757. doi: 10.1136/jitc⁃2021⁃002757.
|
| ［20］ |
Migden MR, Khushalani NI, Chang A, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open⁃label, phase 2, single⁃arm trial［J］. Lancet Oncol, 2020,21（2）:294⁃305. doi: 10.1016/S1470⁃2045（19）30728⁃4.
|
| ［21］ |
Migden MR, Rischin D, Schmults CD, et al. PD⁃1 blockade with cemiplimab in advanced cutaneous squamous⁃cell carcinoma［J］. N Engl J Med, 2018,379（4）:341⁃351. doi: 10.1056/NEJMoa 1805131.
|
| ［22］ |
Hober C, Fredeau L, Pham⁃Ledard A, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous⁃cell carcinomas: real⁃life experience from the French CAREPI study group［J］. Cancers （Basel）, 2021,13（14）:3547. doi: 10.3390/cancers13143547.
|
| ［23］ |
Strippoli S, Fanizzi A, Quaresmini D, et al. Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single⁃center real⁃life experience from Italy［J］. Front Oncol, 2021,11:686308. doi: 10.3389/fonc.2021.686308.
|
| ［24］ |
Grob JJ, Gonzalez R, Basset⁃Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single⁃arm phase II trial （KEYNOTE⁃629）［J］. J Clin Oncol, 2020,38（25）:2916⁃2925. doi: 10.1200/JCO. 19.03054.
|
| ［25］ |
Maubec E, Boubaya M, Petrow P, et al. Phase II study of pembrolizumab as first⁃line, single⁃drug therapy for patients with unresectable cutaneous squamous cell carcinomas［J］. J Clin Oncol, 2020,38（26）:3051⁃3061. doi: 10.1200/JCO.19.03357.
|
| ［26］ |
Hughes B, Mendoza RG, Basset⁃Seguin N, et al. Health⁃related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE⁃629［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1777⁃1790. doi: 10.1007/s13555⁃021⁃00598⁃6.
|
| ［27］ |
Blum V, Müller B, Hofer S, et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases［J］. Eur J Dermatol, 2018,28（1）:78⁃81. doi: 10.1684/ejd.2017.3209.
|
| ［28］ |
Ramella Munhoz R, de Camargo VP, Nader Marta G, et al. Final results of CA209⁃9JC: a phase II study of first⁃line nivolumab in patients with advanced cutaneous squamous cell carcinoma［J］. J Clin Oncol, 2021,32（5_suppl）:S885. doi: 10.1016/j.annonc. 2021.08.1449.
|
| ［29］ |
Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies［J］. J Am Acad Dermatol, 2020,83（5）:1239⁃1253. doi: 10.1016/j.jaad.2020.03. 131.
|
| ［30］ |
Day F, Kumar M, Fenton L, et al. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy［J］. J Immunother, 2017,40（1）:36⁃38. doi: 10. 1097/CJI.0000000000000146.
|
| ［31］ |
García⁃Sancha N, Corchado⁃Cobos R, Bellido⁃Hernández L, et al. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma［J］. Cancers （Basel）, 2021,13（20）:5134. doi: 10.3390/cancers13205134.
|
| ［32］ |
Stevenson ML, Wang CQ, Abikhair M, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab［J］. JAMA Dermatol, 2017,153（4）:299⁃303. doi: 10.1001/jamadermatol.2016.5118.
|
| ［33］ |
Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation［J］. Cancer Treat Rev, 2018,63:48⁃60. doi: 10.1016/j.ctrv.2017.11.008.
|
| ［34］ |
Hober C, Jamme P, Desmedt E, et al. Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab［J］. Ther Adv Med Oncol, 2021,13:175883592 11015493. doi: 10.1177/17588359211015493.
|
| ［35］ |
Chen A, Ali N, Boasberg P, et al. Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab［J］. J Clin Med, 2018,7（1）:10. doi: 10.3390/jcm7010 010.
|
| ［36］ |
Sernicola A, Lampitelli S, Marraffa F, et al. Case report: cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy［J］. F1000Res, 2019,8:933. doi: 10. 12688/f1000research.19149.2.
|
| ［37］ |
Trivedi S, Srivastava RM, Concha⁃Benavente F, et al. Anti⁃EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients［J］. Clin Cancer Res, 2016,22（21）:5229⁃5237. doi: 10.1158/1078⁃0432.CCR⁃15⁃2971.
|
| ［38］ |
Hsu E, Eton O, Patel AV, et al. Combining panitumumab with anti⁃PD⁃1 antibody in cutaneous squamous cell carcinoma of the head and neck after inadequate response to anti⁃PD⁃1 antibody alone［J］. J Drugs Dermatol, 2021,20（8）:901⁃904. doi: 10.36849/ JDD.6175.
|
| ［39］ |
Thai AA, Lim AM, Solomon BJ, et al. Biology and treatment advances in cutaneous squamous cell carcinoma［J］. Cancers （Basel）, 2021,13（22）:5645. doi: 10.3390/cancers13225645.
|
| ［40］ |
Nguyen TA, Offner M, Hamid O, et al. Complete and sustained remission of metastatic cutaneous squamous cell carcinoma in a liver transplant patient treated with talimogene laherparepvec［J］. Dermatol Surg, 2021,47（6）:820⁃822. doi: 10.1097/DSS. 0000000000002739.
|
